#EnvisionYourFuture at #EYPT! We’re #Hiring a Senior Quality Systems Compliance Specialist with a bachelor’s degree to drive compliance activities for development, laboratory and #Manufacutring operations.?? ? #ApplyToday if you are a certified auditor with:?? - Extensive knowledge of US and EU cGMP regulations and guidance?? - 7+ years of FDA regulated industry experience?? - 5+ years of auditing experience??? ? https://lnkd.in/eWKEdTyi?? ? #HybridWork #LifeSciences #Careers #DEI Theresa DiBiase, Sherry Jenkins McHale, Melissa Bedarian, Sean Richards
EyePoint Pharmaceuticals
生物技术研究
Watertown，MA 13,245 位关注者
Delivering Innovation to the Eye? NOW HIRING!
关于我们
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert? technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ? for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
- 网站
-
https://www.eyepointpharma.com
EyePoint Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Watertown，MA
- 类型
- 上市公司
- 领域
- Ophthalmology、Glaucoma、WetAMD、Optometry、Eye Disease和Retinal Disease
地点
-
获取路线
480 Pleasant St., Suite B300
US，MA，Watertown，02472
EyePoint Pharmaceuticals员工
动态
-
This year, Team #EYPT was excited to participate in the Wellable Biotech Challenge for a month-long journey of healthy competition and commitment to wellness! Alongside other #Biotech companies, we spent the month prioritizing our physical and mental well-being through a series of webinars, a steps challenge, and more, as part of our commitment to empowering a healthy workplace. Thank you to everyone who participated in the challenge! Visit our website to learn more about EYPT’s commitment to supporting our employees’ health and wellbeing: https://lnkd.in/diZNHUB??
-
-
WE’RE #HIRING | Finance Planning & Analysis Manager????? ?? Our team is looking for a Finance Planning & Analysis Manager with 4+ years of experience and #biotech knowledge. As a member of the FP&A team at #EYPT, you will be a core contributor in financial forecasting, reporting, systems & analysis for the R&D and G&A functions.?? ? #ApplyToday for an exciting opportunity to provide support and leadership on key strategic business initiatives at a high growth organization!? ? #EnvisionYourFuture #Careers #DEI #LifeSciences? ? https://lnkd.in/eRuWUWxb ??Udaya S., Theresa DiBiase, Sherry Jenkins McHale
-
-
“The new manufacturing facility in Northbridge will support EyePoint’s mission by fostering inclusive collaboration as well as transformational innovation.” – Karli Hanson, Manager, Supply Chain The opening of our new state-of-the-art #Manufacturing facility in #Northbridge, MA is a major milestone for #EYPT that will accelerate our #Clinical development and future #Commercial production for our investigational sustained delivery therapy in #WetAMD and #DME. ??Watch the video below to learn more. #InvestorNews #RetinaPipeline #RetinalDiseases
-
#EYPT’s vision? To develop innovative therapeutics to improve the lives of patients with serious #RetinalDiseases this #DiabeticEyeDiseaseAwarenessMonth and every day. ? With the topline data from our #VERONA clinical trial coming in 2025, we remain committed to addressing the current treatment paradigm for #DME. To learn more about EYPT’s pipeline, visit https://lnkd.in/eN4BpBGi
-
-
David Boyer, MD shares more about the current #WetAMD treatment burden and Phase 3 #LUGANO and #LUCIA clinical trials.? ? EyePoint Pharmaceuticals has partnered with Dr. Boyer to share his own views for educational purposes only; his statements are not intended as medical advice.?
-
-
Our President & CEO, Jay S. Duker, M.D. is in London for the Jefferies London Healthcare Conference! He will share the latest on our #RetinaPipeline and how we are innovating for serious #RetinalDieases, including #WetAMD and #DME. #TuneIn tomorrow for his presentation!?
-
-
#EYPT was honored to support the 2024 Sparkle of Hope Gala, championing Community Hope's efforts to offer life-changing support, services and housing to our veterans and their families.
-
-
At the Guggenheim’s Inaugural Global Healthcare Conference, #EYPT President & CEO, Jay S. Duker, M.D. delivered a #FiresideChat to highlight the latest innovations in our #RetinaPipeline, including more on our Ph3 #WetAMD and Ph2 #DME programs. Listen to the replay here: https://lnkd.in/ehhZmsij ? #EYPT #InvestorNews
-
-
Today, #EYPT President & CEO, Jay S. Duker, M.D. is in Terranea, CA to deliver a #FiresideChat at the UBS Global Healthcare Conference. #TuneIn to learn more about how we are innovating for patients with serious #RetinalDiseases, including the latest on our Ph3 #WetAMD and Ph2 #DME programs. ? #InvestorNews #RetinalDiseases #Ophthalmology
-